UK markets close in 1 hour 15 minutes

Aerie Pharmaceuticals, Inc. (AERI)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
12.46+0.05 (+0.40%)
As of 10:12AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close12.41
Open12.70
Bid12.49 x 800
Ask12.55 x 900
Day's range12.44 - 12.63
52-week range9.01 - 26.26
Volume27,879
Avg. volume728,723
Market cap583.312M
Beta (5Y monthly)0.71
PE ratio (TTM)N/A
EPS (TTM)-4.19
Earnings date05 Nov 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est27.17
  • Bausch (BHC) Begins Second Phase III Study on NOV03 for DED
    Zacks

    Bausch (BHC) Begins Second Phase III Study on NOV03 for DED

    Bausch (BHC) starts a second phase III study on its investigational treatment NOV03 for dry eye disease related to Meibomian gland dysfunction.

  • Aerie (AERI) Gets Positive CHMP Opinion for Roclanda in EU
    Zacks

    Aerie (AERI) Gets Positive CHMP Opinion for Roclanda in EU

    Aerie (AERI) receives positive CHMP opinion for Roclanda for reduction of elevated intraocular pressure in adult patients.

  • Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the European Union
    Business Wire

    Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the European Union

    Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorisation application (MAA) for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. The recommended indication is the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.